Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States.

Key Points

• The aim is to compare outcomes between CAR T therapy and standard therapy in advanced follicular lymphoma.
• Conducted a real-world analysis
• Compared treatment outcomes after CAR T versus standard therapy
• Assessed time to next treatment (TTNT) and time from treatment initiation (TFI)
• Evaluated FL-related costs
• CAR T therapy was associated with longer TTNT compared to standard therapy
• CAR T therapy resulted in longer TFI
• Downstream FL-related costs were lower with CAR T therapy